Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19(+)B-cell repopulation

Detalles Bibliográficos
Autores principales: Sahi, Nitin Kumar, Abidi, Syed Muhammad Ali, Salim, Omar, Abraham, Roby, Kalra, Seema, Al-Araji, Adnan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474870/
https://www.ncbi.nlm.nih.gov/pubmed/34627005
http://dx.doi.org/10.1016/j.msard.2021.103287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474870/
https://www.ncbi.nlm.nih.gov/pubmed/34627005
http://dx.doi.org/10.1016/j.msard.2021.103287

Ejemplares similares